NYSE:TEVATeva Pharmaceutical Industries Stock Price, Forecast & News

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TEVA stock has increased by 27.6% and is now trading at $11.50.
View which stocks have been most impacted by COVID-19.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 10 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) issued its quarterly earnings results on Wednesday, August, 5th. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of $0.53 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to analysts' expectations of $3.94 billion. Teva Pharmaceutical Industries had a net margin of 0.03% and a return on equity of 17.88%. The company's revenue for the quarter was down 7.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.60 EPS.
View Teva Pharmaceutical Industries' earnings history.

Teva Pharmaceutical Industries updated its FY20 earnings guidance on Wednesday, August, 5th. The company provided earnings per share guidance of $2.30 to $2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.49. The company issued revenue guidance of $16.6 billion to $17 billion, compared to the consensus revenue estimate of $16.83 billion.

18 brokers have issued 12 month price objectives for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $12.36 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries.

News coverage about TEVA stock has been trending positive this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a daily sentiment score of 2.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries saw a decrease in short interest in December. As of December 31st, there was short interest totaling 57,460,000 shares, a decrease of 14.7% from the December 15th total of 67,380,000 shares. Based on an average daily volume of 19,350,000 shares, the short-interest ratio is presently 3.0 days.
View Teva Pharmaceutical Industries' Short Interest.

Some companies that are related to Teva Pharmaceutical Industries include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), UCB (UCBJF), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), BioMarin Pharmaceutical (BMRN), Beigene (BGNE), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics (HZNP), Catalent (CTLT) and Sarepta Therapeutics (SRPT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), Bank of America (BAC), Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by many different institutional and retail investors. Top institutional investors include Menora Mivtachim Holdings LTD. (1.64%), Phoenix Holdings Ltd. (1.07%), FMR LLC (0.75%), Harel Insurance Investments & Financial Services Ltd. (0.70%), Swiss National Bank (0.40%) and Sumitomo Mitsui Trust Holdings Inc. (0.38%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Rosemary A Crane, Sol J Barer and Sven Dethlefs.
View institutional ownership trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Psagot Investment House Ltd., Alberta Investment Management Corp, State of Wisconsin Investment Board, Personal Resources Investment & Strategic Management Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Cambridge Investment Research Advisors Inc., and Cubist Systematic Strategies LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Richard Daniell, and Rosemary A Crane.
View insider buying and selling activity for Teva Pharmaceutical Industries.

TEVA stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Orbimed Advisors LLC, Menora Mivtachim Holdings LTD., Teacher Retirement System of Texas, Harel Insurance Investments & Financial Services Ltd., Phoenix Holdings Ltd., Bailard Inc., and Bank of Montreal Can.
View insider buying and selling activity for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $11.50.

Teva Pharmaceutical Industries has a market capitalization of $12.56 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]